Abstract
Hepatotoxicity from paracetamol is of great concern because of the considerable number of patients who develop severe toxicity from this drug. A group of senior medical practitioners, academics and scientists were brought together on June 29 and 30, 2009 by the Food and Drug Administration of USA (FDA) with the aim of providing advice on how to limit the number of cases of hepatotoxicity due to paracetamol in USA. The most contentious recommendations were the reduction in the dose of paracetamol to 650 mg and the elimination of prescription combination products of paracetamol and opiates. The first recommendation indicates that many members of the committee consider, despite much evidence to the contrary, that therapeutic doses of paracetamol (up to 4 g daily) are associated with a significant incidence of hepatotoxicity. The second recommendation, if accepted by FDA, will require major changes in the therapeutic use of paracetamol and opiates. Adoption of these two recommendations may lead to the increased use of NSAIDs with the potential of increasing incidence of NSAIDs-related adverse reactions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bachert C, Chuchalin AG, Eisebitt R et al (2005) Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose ranging study. Clin Ther 27:993–1003
Bateman DN (2009) Limiting paracetamol pack size: has it worked in the UK? Clin Toxicol 47(6):536–541
Benson GD (1983) Acetaminophen in chronic liver disease. Clin Pharmacol Ther 33:95–101
Brune K, Hinz B, Otterness I (2009) Aspirin and acetaminophen: should they be available over the counter? Curr Rheumatol Rep 11:36–40
Buckley NA, Gunnel D (2007) Does restricting pack size of paracetamol (acetaminophen) reduce suicides? PLoS Med 4(4):e152
Dart RC, Bailey E (2007) Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 27:1219–1230
Dart RC, Kuffner EK, Rumack BH (2000) Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 7:123–134
den Hertog HM, van der Worp HB, van Gemert HMA et al (2009) The paracetamol (acetaminophen) in stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 8:434–440
Fabris P, Palma MD, de Lalla F (2001) Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon-α. Ann Intern Med 134:345
FDA Background. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf. Accessed 22 January 2010
FDA Pack Size. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM168619.pdf. Accessed 22 January 2010
FDA Transcript, June 29. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM174697.pdf. Accessed 27 January 2010
FDA Transcript, June 30 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM174699.pdf. Accessed 27 January 2010
Forrest JA, Adriaenssens P, Finlayson ND, Prescott LF (1979) Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol 15:427–431
Johnson GK, Tolman KG (1977) Chronic liver disease and acetaminophen. Ann Intern Med 87(3):302–304
Khan SA, Shah N, Williams R, Jalan R (2006) Acute liver failure: a review. Clin Liver Dis 10:239–258
Krenzelok EP (2009) The FDA acetaminophen advisory committee meeting–what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol 47:784–789
Larson AM, Polson J, Fontana RJ et al (2005) Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42:1364–1372
Lee WM (2004) Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure. Hepatology 40:6–9
McIntyre N (1999) The general management of liver disease. In: Bircher J, Benhamou J-P, McIntyre N et al (eds) Oxford Textbook of Clinical Hepatology. Oxford University Press, Oxford, UK, pp 1917–1922
McQuay HJ, Moore RA (2007) Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. Br J Clin Pharmacol 63(3):271–278
Morgan OW, Griffiths C, Majeed A (2007a) Interrupted time-series analysis of regulations to reduce paracetamol (acetaminophen) poisoning. PLoS Med e105
Morgan O, Hawkins L, Edwards N, Dargan P (2007b) Paracetamol (acetaminophen) pack size restrictions and poisoning severity: time trends in enquiries to a UK poisons centre. J Clin Pharm Ther 32(5):449–455
Nourjah P, Ahmad SR, Karwoski C, Willy M (2006) Estimates of acetaminophen (Paracetamol)-associated overdoses in the United States. Pharmacoepid Drug Saf 15:398–405
Prescott LF (2000a) Therapeutic misadventure with paracetamol: Fact or fiction. Am J Ther 7:99–114
Prescott LF (2000b) Paracetamol, alcohol and the liver. Br J Clin Pharmacol 49:291–301
Robinson D, Smith AM, Johnston GD et al (2000) Severity of overdose after restriction of paracetamol availability: retrospective study. Br Med J 321:926–927
Temple AR, Lynch JM, Vena J et al (2007) Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen. Clin Toxicol 45:36–44
Weil K, Hooper L, Afzal Z et al (2007). Paracetamol for pain relief after surgical removal of lower wisdom teeth. Cochrane Database Syst Rev 3:CD004487
Zapater P, Lasso de la Vega MC, Horga JF et al (2004) Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Aliment Pharmacol Ther 20:29–36
Acknowledgments
Research projects of GG Graham and A Graudins on the mechanism of action and pharmacokinetics of paracetamol, respectively, have been supported by GlaxoSmithKline Australia Pty Ltd who market paracetamol. RO Day has been a member of an advisory group for GlaxoSmithKline Australia Pty Ltd.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s10787-010-0039-3
Rights and permissions
About this article
Cite this article
Graham, G.G., Day, R.O., Graudins, A. et al. FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. Inflammopharmacol 18, 47–55 (2010). https://doi.org/10.1007/s10787-010-0036-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-010-0036-6